ASPI · ASP Isotopes $3.13 -0.11 (-3.39%) 2026-SEP-18 12:48 EST

ASP Isotopes is a company that separates isotopes — different weights of the same chemical element — and sells the purified versions. That sounds academic, but each product has a specific customer: silicon-28 is the ultra-pure silicon quantum-computing chips need; ytterbium feeds medical isotope production; and through Renergen the company owns a South African gas field producing helium, which cannot be manufactured and escapes the atmosphere for good once released. It also owns PET Labs, a nuclear-medicine business, and Quantum Leap Energy (QLE), a nuclear-fuel venture it intends to spin out to shareholders. So one listed share is really a bundle of four or five separate businesses at different stages.

The point of this particular post is that a member of the community sat on a small (about ten people) investor call run by Red Chip with the CEO, Paul Mann, and Renergen's COO, and wrote up what was said. The first thing worth knowing is what was not said: Mann "doesn't discuss" the share price or the valuation, on the grounds that valuing the company is the investor's job. So nothing here is management talking the stock up — it is a status report on plants, contracts and paperwork.

The status report is broadly good. The helium plant is being commissioned with first shipments due early September. The gas is being sold under take-or-pay contracts of five to fifteen years — meaning the customer pays for the agreed volume whether or not they take delivery, which turns a commodity into something much closer to a rent. The first deal was struck at $600 per mcf (an "mcf" is a thousand cubic feet of gas) and management says it is now seeing prices "potentially up to $1,000." A $750m debt package ($500m from the US development-finance agency DFC, $250m from Standard Bank) is waiting behind three checkable conditions, plus a further $250m of equity that Mann expects to raise easily. On the enrichment side, silicon-28 has reached 99.5% purity but the quantum-computing specification is 99.9995% — not there yet — while the much larger market for merely 99% material is one they intend to attack anyway; ytterbium moves to continuous production next month, at which point it can ship.

Two structural events are pending. The QLE spin-out — where existing ASPI holders are handed shares in the nuclear-fuel business — cannot happen before 13 September for US capital-gains reasons, and the exchange ratio has already been decided but not published (it is not one-for-one). It is waiting on a contract with Fermi, the operator of a Texas plant, which itself is waiting on a couple more tenants signing up. Separately, some odd-looking recent purchases (two properties, some gold) are simply a device to keep the company classified as a trading company for tax purposes while a Hong Kong building business is sold — they will likely be resold once a Kazakh transaction with Cove Kaz Capital closes, which is stuck on the mundane problem of finding an auditor for the asset.

The author's own conclusion is not a price target but a temperament argument. Twenty-odd years ago he held a small UK software company, GB Group, through four years of delays and two profit warnings while the share price went 33p → 50p → 15p → 33p and other investors complained bitterly about management. He sold, made about £2,500 — and then watched it run to nearly 1000p, which on his 600,000 shares in a tax-free account would have been about £6m. He is explicit that he is not predicting the same outcome here, only that the tone of the complaints "does seem awfully familiar," and that everyone should do their own work.

Whose view this is matters. Everything below is the chief executive presenting his own company at an investor conference — a pitch, not an outside assessment. It is worth archiving because it is unusually specific: Mann puts dated milestones, per-unit prices and division-by-division profit targets on the record, which is exactly the kind of thing that can be checked against reality in six months.

ASP Isotopes runs four businesses under one listed share. PET Labs makes radioactive medicines for cancer treatment in South Africa — it grew revenue more than 50% in the first half and management expects revenue to double this year against last, with its first in-house drug candidates (AlphaNostics) entering human trials. The isotope plants separate three specific materials: silicon-28 (ultra-pure silicon for faster chips and for quantum computers), carbon-14 (a research and drug-development material at $24,000 a gram) and ytterbium-176 (the feedstock for a fast-growing class of cancer drugs, also about $20,000 a gram). Renergen is the South African gas field that produces helium and liquefied natural gas. And Quantum Leap Energy is a nuclear-fuel venture the company intends to hand out to its own shareholders as a separate listed company by the end of the year.

The headline goal is $300m of EBITDA in 2031 — EBITDA being roughly the cash profit a business throws off before interest, tax and accounting depreciation. Mann breaks it into electronic gases ($150–300m), natural gas and LNG ($100–200m), medical isotopes ($40–100m) and radiopharmaceuticals ($40–100m). His own sanity check is that helium and LNG alone could produce the whole $300m at the prices being discussed today, which means the target does not require every division to work.

The most useful thing he says is the awkward one. The silicon-28 plant has been late, and he gives a clean root cause: the plant needs more than 400 compressors, all of which must be gas-tight to reach the required purity, and the Swiss manufacturer supplied them with faulty rubber O-ring seals. Each compressor is being taken apart and re-sealed by hand in a clean room. The distinction he is drawing — a defective bought-in part rather than a flaw in the process itself — is the difference between a schedule problem and an existential one, and it is checkable: 48 of the eventual 96–100 stages are now running and enriching correctly.

ASP Isotopes enriches stable isotopes — not the radioactive kind used in nuclear reactors, but specialty isotopes used in medical imaging (Molybdenum-100 for PET/CT scans), research, and industrial applications. The enrichment technology uses aerodynamic separation (the "ASP" process) rather than centrifuges, giving it a different cost curve and a different geopolitical risk profile than conventional uranium enrichers.

Two developments this issue: first, a helium take-or-pay contract locked in at >$600/MCF — well above current spot — de-risks a meaningful revenue stream. Second, the Noble Africa spin via ENDRA reverse merger diversifies the asset base into African noble gas and specialty isotope supply, adding geographic and commodity breadth. The stock is -11% on dilution concerns from the ENDRA transaction; Mart still holds at $3.84 cost basis, 100% allocated, characterising the drawdown as a bump in a long runway rather than a thesis break. Neutral stance reflects the dilution uncertainty, not a change in long-term conviction.

ASPI enriches Silicon-28 — a highly purified form of silicon where one of the naturally-occurring isotopes (Si-29) has been removed. Why does that matter? When you build quantum computer chips on natural silicon, the Si-29 atoms act like constant radio static, knocking quantum bits out of their computing state before they can do any useful work. Strip Si-29 out to extremely high purity (above 99.99%) and those qubits can hold their quantum state roughly a thousand times longer — the difference between a laboratory experiment and a processor that can actually run algorithms. There is also a commercial benefit for regular chips: pure Si-28 conducts heat about 50% better than natural silicon, which matters a great deal for next-generation AI accelerator design where heat is the binding constraint.

This issue ASPI announced the first 18 stages of their Silicon-28 enrichment plant in Pretoria have been successfully restarted and have been running at target enrichment levels for over three weeks, with Q3 2026 commercial shipments now guided. The stock moved +25% on the news. Mart's read: positive on the margin — this is real operational progress after roughly a year of setbacks — but he is explicitly not popping the champagne. The original commercial shipment target was Q2 2025; it has now been revised at least six times in 18 months. The Q1 earnings call held just six days before this release was still guiding mid-year, and the new release quietly moved it to Q3 without flagging the change. The inflection that actually matters is when Silicon-28 revenue hits the income statement for the first time. Until then, the company has been promising the same milestone on a rolling basis.